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Development, characterisation and in vitro evaluation of 
lanthanide-based FPR2/ALX-targeted imaging probes 
Tamara Boltersdorfa, Junaid Ansarib, Elena Y. Senchenkovab, Lijun Jianga, Michael Cooganc, Felicity 
N. E. Gavinsb,d*, Nicholas J. Longa,* 
We report the design, preparation and characterisation of three small-molecule, Formyl Peptide Receptor (FPR)-targeted 
lanthanide complexes (Tb.14, Eu.14 and Gd.14). Long-lived, metal-based emission was observed from the terbium complex 
(τH2O = 1.9 ms), whereas only negligible lanthanide signals were detected in the europium analogue. Ligand-centred emission 
was investigated using Gd.14 at room temperature and 77 K, leading to the postulation that metal emission may be 
sensitised via a ligand-based charge transfer state of the targeting Quin C1 unit. Comparatively high longitudinal relaxivity 
values (r1) for octadentate metal complexes of Gd.14 were determined (6.9 mM-1s-1 at 400 MHz and 294 K), which could be 
a result of a relative increase in twisted square antiprism (TSAP) isomer prevalence compared to typical DOTA constructs (as 
evidenced by NMR spectroscopy). In vitro validation of concentration responses of Tb.14 via three key neutrophil functional 
assays demonstrated that the inflammatory responses of neutrophils (i.e. chemotaxis, transmigration and granular release) 
remained unchanged in the presence of the compound. Using a time-resolved microscopy set-up we were able to observe 
binding of the Tb.14 probe to stimulated human neutrophils around the cell periphery, while in the same experiment with 
un-activated neutrophils, no metal-based signals were detected. Our results demonstrate the utility of Tb.14 for time-
resolved microscopy with lifetimes several orders of magnitude longer than autofluorescent signals and a preferential 
uptake in stimulated neutrophils. 
Introduction 
The inflammatory response is implicated in the progression of a 
variety of disease states including Alzheimer’s Disease,1 stroke,2 
sickle cell disease3 and cancer4 and often the extent of 
inflammation is a key factor controlling disease prognosis. As a 
result, there is interest in gaining mechanistic insights into the 
physiological processes underlying inflammation in order to 
address clinical issues and provide screening tools for drug 
discovery programmes.5  
The Formyl Peptide Receptor (FPR) family6 comprising FPR1, 
FPR2/ALX (also known as the lipoxin A4 receptor, and previously 
termed FPR-like 1 [FPRL1, but not to be confused with FPR1, 
nomenclature detailed in reference6]) and FPR3 (also known as 
FPRL2) in humans are categorised as G-protein coupled 
receptors (GPCR) and have attracted interest as a result of their 
role in modulating both pro- and anti-inflammatory 
pathways7,8,9 during all phases of the inflammatory response 
(including initiation, chemotactic signaling, propagation, 
resolution and tissue repair).  Amongst these, FPR1 and 
FPR2/ALX are expressed on the cell surface of human 
neutrophils and can induce chemotaxis, mobilise adhesion 
molecules and inhibit migration of these immune cells.6 
Although these receptors are also known to be upregulated in a 
variety of disease conditions,10 the understanding of their 
specific physiological functions still remains limited, creating a 
need to prepare probes that enable their roles to be studied in 
a biological context.11,7 
Compounds to enable targeting of FPR1 and FPR2/ALX to track 
neutrophils in inflammatory conditions have been previously 
reported as imaging agents for example, in magnetic resonance 
imaging (MRI),12 positron emission tomography (PET),13 
optical14 and single-photon emission computed tomography 
(SPECT).15,16 These constructs, however, have been derived 
from the peptide-based FPR1 antagonist cinnamoyl-F-(D)L-F-
(D)L-F (cFLFLF), which is highly hydrophobic and often results in 
poor target to background ratios, necessitating incorporation 
of, for instance, large PEGylated chains.17 Another strategy 
reports synthetic modifications of the potent, peptide-based 
FPR agonist formyl-Met-Leu-Phe (fMLF) to prepare agents for 
both optical- and radio-imaging of FPRs.18,19,20 These 
compounds, however, are unselective for receptor subtype 
(FPR1 or FPR2/ALX) and the known high potency of the modified 
agonist ligand fMLF results in a risk of unwanted receptor 
activation,6 possibly even causing an inflammatory response 
when using the system for imaging. 
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To circumvent the issues encountered with peptide systems, 
small-molecule, FPR-specific ligands that are synthetically and 
metabolically more robust, as well as cheaper to prepare and 
modify,21 could provide a convenient alternative. Large-scale 
screening for such binding motifs have been previously 
performed, and a non-peptidic, mild FPR2/ALX agonist, 4-
butoxy-N-[2-(4-methoxy-phenyl)-4-oxo-1,4-dihydro-2H-
quinazolin-3-yl]-benzamide (Quin C1),22 was identified in 2004. 
The compound was assessed for its concentration dependence 
in vitro, and in vivo properties were evaluated,22,23 but to our 
knowledge it has not been derivatised to form an imaging agent 
for FPR2/ALX. 
Fluorescence microscopy is a widely used technique for cellular 
imaging and pre-clinical models that surpasses many other 
modalities in terms of sensitivity and spatial resolution, allowing 
systems to be investigated on a cellular and subcellular level.24 
Although numerous targeted and fluorescent probes have been 
designed to enable visualisation of surface receptors by 
fluorescence microscopy, these are often accompanied with 
various drawbacks.25 Amongst these are poor photostability, 
difficulty in separating signals from autofluorescence, large 
probe sizes, as well as sometimes restricted labelling sites when 
dealing with peptide-based targeting groups.26,27 
Time-resolved microscopy relies on detection of the 
luminescence lifetimes of a sample, which are not substantially 
affected by photobleaching events. In addition, if a sufficiently 
long-lived probe is used, this can create signal differences of 
several orders of magnitude between compound and cellular 
background, allowing for a much more accurate picture of the 
agent within a cell.28,29 For example, long-lived iridium probes 
have been developed to image cancer cells30,31 and for uses in 
live zebrafish.32,33 
Stable lanthanide(III) chelates based on terbium or europium 
often have highly desirable properties for cellular imaging: their 
emission is long-lived (up to ms range), the separation between 
excitation and emission bands is large and metal-based 
emission is characterised by sharp, distinctive peaks that are 
only minimally altered by different ligand surroundings.34,35,36,37 
Recently, the first and, to the best of our knowledge, only 
example of time-resolved FPR2/ALX imaging in cells has been  
reported using an iridium complex coupled to a peptidic 
FPR2/ALX agonist.38 However, the probe was designed based on 
a potent FPR2/ALX agonist and caused a dose-dependent 
response in human umbilical vein endothelial cells (HUVECs), 
altering cellular properties and rendering it not ideal as an 
imaging agent.38 
Therefore, by combining the small-molecule targeting group 
Quin C1 with a stable Tb(III) chelate, we aimed to prepare a 
probe that does not change the functional response of the 
neutrophil, but allows for time-resolved imaging of these cells 
(i.e. inflammation) via FPR2/ALX (Figure 1). Furthermore, 
differentiation of compound luminescence from an 
autofluorescent background (which is hard to distinguish in 
traditional fluorophores) allows for visualisation of compound 
uptake patterns within the neutrophil in both its activated state 
(when prior stimulation has occurred using an inflammatory 
stimulus, tumor necrosis factor alpha [TNFα]) and in an un-
activated state (using phosphate buffered saline [PBS] as a 
control). By complexing Gd(III) instead of Tb(III), we were also 
able to prepare a compound with r1 relaxivity values of 6.9 mM-
1s-1, which are increased compared to typical octadentate 
structures (where r1 = 3 – 5 mM-1s-1).39  The Eu(III) analogue was 
constructed to enable the macrocyclic conformational 
equilibria to be investigated by 1H-NMR spectroscopy and 
therefore provide insight into the twisted square antiprism 
(TSAP) to square antiprism (SAP) geometry ratios of the 
complex.   
Results and discussion 
Synthetic procedures 
The FPR2/ALX targeting unit Quin C1 (6) was prepared according 
to modified procedures previously described22 and obtained as 
a crystalline solid after purification by column chromatography 
(Figure 2 and 3). Compound 6 was further reacted with 
chloroacetyl chloride to produce 7. Next, a DOTA-derived, 
macrocyclic scaffold was prepared following known 
protocols.40,41,42 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-
tetraacetic acid (DOTA)-derived macrocycles are commonly 
used for biomedical applications and their octadentate 
lanthanide coordination complexes are characterised by high 
kinetic inertness and thermodynamic stability under 
physiological conditions.43 In brief, the mono-tert-
butyloxycarbonyl protected compound 9 was prepared and 
reacted with chloroacetyl chloride, before combination with the 
tert-butyl protected 1, 4, 7, 10- tetraazacyclododecane-1, 4, 7-
trisacetic acid (DO3A) macrocycle to yield 11. Subsequent 
deprotection with trifluoroacetic acid and dichloromethane 
unmasked the amine terminal ligand scaffold 12 in high yields.  
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Metal complexation was carried out using terbium or europium 
trifluoromethanesulfonate salts or gadolinium chloride 
hexahydrate in water at pH 5.5 to produce the lanthanide 
complexes Tb.13, Eu.13 and Gd.13. The compounds were 
purified by dialysis using a 500-1000 Da molecular weight cut-
off cellulose membrane, allowing separation of excess metal 
salts. Absence of free lanthanide ions was ascertained using the 
xylenol orange indicator test. To afford FPR2/ALX targeted 
lanthanide complexes, Tb.13, Eu.13 and Gd.13 were combined 
with the functionalised targeting moiety 7. The resulting 
compounds Tb.14, Eu.14 and Gd.14 were isolated after 
Sephadex size exclusion chromatography, dissolved in a 




The thus far unreported crystal structure of Quin C1 (6) was 
acquired by slow evaporation from methanol at room 
temperature and is depicted in Figure 3. The compound was 
found to crystallise as a mixture of both the R and S enantiomer 
(chiral carbon: C3), which stacked alternately. In the solid state, 
two twists within the molecule along the C3-C24 bond and the 
C12-C13 bond were observed, creating three planes. Bond 
lengths and angles are listed in the supplementary information. 
Intermolecular H-bonding between the O1 and H4A (on N4) 




Steady-state and time-gated luminescence and absorption 
spectra of Tb.14 were recorded in aerated methanol solutions 
(Figure 4A). Excitation at 350 nm yielded an emission maximum 
at 441 nm. Two maxima at 227 nm and 347 nm (λem= 440 nm) 
were apparent within the excitation spectrum. Upon 
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characteristic terbium emission bands with maxima at 490 nm, 
546 nm, 586 nm and 620 nm arising from 5D4 → 7FJ transitions, 
for J = 6, 5, 4 and 3 respectively were apparent within the 
spectrum, demonstrating sensitisation of the lanthanide via the 
ligand chromophore. Metal-centred luminescence lifetimes of 
Tb.14 were recorded in water and deuterium oxide and their 
decays were fitted to a single-exponential function (Figure S1, 
ESI). The resulting values were determined as τD2O = 2.8 ms and 
τH2O = 1.9 ms. Using the empirical relationship between the 
lifetimes of a species in H2O and D2O and the number of bound 
water molecules respectively,44,45 the hydration number (q-
value) was determined as q = 0.8, suggesting an octadentate 
ligand environment and a 9-coordinate metal centre.  
In order to assess the short-lived, ligand-based components of 
the emissio, Time-Correlated Single Photon counting (TCSPC) 
studies were undertaken on a PicoQuant FluoTime 300 
equipped with a 375 nm picosecond pulsed laser. The resulting 
decay curves for short lifetimes were fitted using a numerical 
reconvolution algorithm to account for the finite Instrument 
Response Function (IRF) using FluoFit software. Interestingly, 
the fluorescence decay obtained for Tb.14 by this method could 
not be fitted to a single exponential decay curve, but instead 
was best fitted to a biexponential decay with 2 components 
with ns range lifetimes of τ1 = 11 ns (approximately 85% 
fractional intensity) and τ2 = 3 ns (approximately 15% fractional 
intensity) (Figure S2, ESI). This phenomenon is tentatively 
assigned to dual emission occurring from two orthogonal 
components of the organic system, which is supported by the 
observation of two ligand-based emission processes in the 
complex (see below). The preferred non-planar conformation 
around the diacyl hydrazine linkage will prevent efficient 
relaxation through dipole-dipole interactions and preserve 
independent emission from each component (see Figure 3). 
In the europium complex (Eu.14), weak lanthanide emission 
was observed upon application of a time gate, while steady 
state emission spectra were comparable to those of the terbium 
analogue (λmax = 451 nm for emission and λmax = 348 nm for the 
longest wavelength excitation band in methanol, Figure S3, ESI). 
The faint lanthanide-based emission is likely indicative of a poor 
energy match between the relevant excited state within the 
antenna unit and the 5D0 europium emissive state.  
Typically, population of the lanthanide excited state is known to 
proceed via an energy transfer process (sensitisation).46 Often, 
this pathway occurs through ligand excitation, intersystem 
crossing to the ligand-based excited triplet state followed by an 
energy transfer to the relevant emissive lanthanide state.47 
Gadolinium-centred emission occurs within the UV range of the 
spectrum and thus does not interfere with the visible light 
ligand-based emission, making the gadolinium analogue (Gd.14) 
a convenient lanthanide complex model to study ligand-based 
emission.48 
To observe phosphorescence (T1 → S0) from the ligand triplet 
energy level (T1) which is typically considered responsible for 
sensitising the metal unit, emission spectra of Gd.14 under low 
temperature conditions were recorded (to minimise triplet 
state deactivation by non-radiative processes). The obtained 
spectra revealed that upon cooling to 77 K in ethanol, an intense 
transition at 416 nm and a weak maximum at 539 nm were 
apparent (Figure 4B). The weak, lower energy band was  
tentatively assigned to the ligand-centred triplet state, whereas 
the shift to higher energy emission at low temperature (441 nm 
at room temperature to 416 nm at 77 K) is indicative of a charge 
transfer process.49 These results led us to hypothesise that the 
ligand-based emission seen at room temperature could result 
from a thermally activated ligand charge transfer band 
(supported by the broad, structureless nature of emission and 
absorption bands with large Stokes’ shifts), while a shift to 
higher energies of that band are observed at low temperature. 
The data further led us to hypothesise that an unusual 
lanthanide sensitisation pathway in the terbium complex may 
occur via the energetically well-matched charge transfer band 
(at 22,575 cm-1 compared to the Tb(III) 5D4 excited state at 
20,400 cm-1),50 whereas the tentatively assigned ligand triplet 
state (at 18,553 cm-1) appears too low in energy for terbium 
sensitisation. Additionally, our results suggest that neither the 
ligand triplet state nor the charge transfer state can efficiently 
sensitise europium emission (Figure S3, ESI). 
Similar sensitisation pathways via an antenna charge transfer 
excited state have been studied extensively for Eu(III), Yb(III) 
and Nd(III) complexes,51,52 whereas examples of intra ligand 
charge transfer (ILCT)-sensitised Tb(III) emission are rare.49 This 
sensitisation pathway, which proceeds via the strong, ligand-
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based absorption band that is typically associated with an ILCT 
state, could be harnessed for microscopy applications.  
 
Investigation into conformational equilibria 
Ln(III)-DOTA complexes form two well characterised 
stereoisomers that are visualised as a square antiprism (SAP) 
isomer and a twisted square antiprism (TSAP) isomer. The two 
isomers can interconvert in solution and differ in the twist angle 
between the oxygen and the nitrogen binding planes.53,54 The 
equilibrium between the two species can be tuned by different 
factors55,56,57 and is particularly relevant to gadolinium 
complexes with uses in MRI, as the TSAP geometry is often 
associated with substantially increased water exchange rates 
and correspondingly higher relaxivity values.58,59 
Within the 1H-NMR spectrum of Eu.14 (Figure S4A, ESI) 
resonances consistent with the SAP axial proton region (29 - 35 
ppm) and the minor TSAP isomer axial protons (between 10 and 
14 ppm) were present.60 The signals appear broadened 
compared to those observed in the starting material (Figure 
S4B, ESI) and more than four proton environments were 
observed, likely arising from further, superimposed 
conformational equilibria.61 In addition, the spectrum suggests 
an increase in the amount of the minor TSAP isomer compared 
to the starting material (estimated prevalence by relative 
integration 0.36:1), consistent with previous reports that 
increasing steric demands on the lanthanide ion leads to an 
increased preference for the TSAP geometry.57 
 
Relaxometric measurements 
Next, the longitudinal relaxation time (T1) of Gd.14 in water was 
determined at distinct molar concentrations (at 400 MHz and 
294 K) using inversion recovery experiments. The resulting 
relaxivity values were estimated according to a graphical 
procedure62 and a value of 6.9 mM-1s-1 was measured for Gd.14 
in water. This value is surprisingly high, considering that low 
molecular weight, octadentate gadolinium chelates typically 
exhibit r1 values of 3 – 5 mM-1s-1,39 which may be driven by the 
observed increase in TSAP isomer compared to the starting 
material. Although used as an indication, this value does not 
predict how well the compound would perform in a more 
complicated in vitro or in vivo setting. 
 
In vitro viability assessment 
For Tb.14 to provide a useful platform for imaging inflammation 
via FPR2/ALX, it is crucial to ensure the compound itself does 
not modify the normal immunological functions of neutrophils 
(such as their ability to move towards a chemical gradient, 
transmigrate through an endothelial layer and their granular 
content release e.g. myeloperoxidase [MPO]). With this in mind, 
neutrophils were pre-treated with saline control or varying, 
biologically relevant concentrations of the compound (10-6, 10-
7, 10-8 and 10-9 M) and neutrophil functional responses were 
analysed using three distinct assays to assess chemotaxis, 
transmigration and MPO release (Figure 6). As the initial 
recruitment of neutrophils in inflammation is driven by their 
ability to move towards a chemical signal or chemoattractant 
(e.g. leukotriene B4 [LTB4]), we tested the effect of neutrophils 
to migrate towards LTB4 (10-6 M) or PBS vehicle with and 
without pre-treatment with Tb.14 (Figure 5). The data collected 
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migrated in response to LTB4 and neutrophils migrated in 
response to vehicle) and statistical analysis confirmed that at 
relevant compound concentrations, no significant change in 
neutrophil mobility was observed compared to the PBS control 
(Figure 6A). 
An important part of the inflammatory response is the ability of 
neutrophils to extravasate from blood vessels to the site of 
tissue injury.63 To simulate this biological function, neutrophils 
were incubated with PBS control or varying concentrations of 
Tb.14 (10-6, 10-7, 10-8 and 10-9 M) and their ability to migrate 
through a HUVEC layer towards a chemoattractant (LTB4) was 
assessed. Figure 6B shows that the compound did not modify 
the ability of neutrophils to transmigrate towards LTB4 at any of 
the concentrations tested. Although there appeared to be a 
trend towards less neutrophils migrating towards LTB4 when 
treated with the lower Tb.14 concentrations (i.e. 10-7 to 10-9M), 
this was not significant when compared to the LTB4 control. 
Equally, all groups (i.e. the LTB4 control group and all Tb.14 
concentrations tested) produced significant effects when 
compared with the PBS control group, authenticating the use of 
Tb.14 as an imaging agent.  
Under inflammatory conditions neutrophils release reactive 
species from their intracellular granules in order to eliminate 
invading pathogens. Amongst these granular proteins, 
myeloperoxidase (MPO, a marker of neutrophil activation) is 
known to perform anti-microbial functions as well as to 
contribute significantly to neutrophil dependent 
inflammation.64 To test whether presence of Tb.14 changes 
MPO production in activated neutrophils compared to the 
control, we assessed MPO activity in neutrophils that had 
transmigrated through an endothelial (HUVEC) layer. In this 
assay, we found a concentration dependent response of Tb.14 
on neutrophil MPO production. At high concentrations (10-6 M), 
Tb.14 did not affect the ability of neutrophils to release their 
MPO, however, we found that an attenuation of granular 
release occurred at 10-8 M, whereas the presence of certain 
Tb.14 concentrations (10-7 M and 10-9 M) produced little MPO 
effects. These results suggest that Tb.14 at a concentration of 
10-6M is more suitable as an imaging agent as this concentration 
does not inhibit the ability of neutrophils to release their MPO 
i.e. perform their immune response. 
 
Proof of concept time-resolved microscopy investigation  
Human neutrophils were isolated and pre-treated with vehicle 
(PBS) or stimulated with TNFα. Neutrophils were subsequently 
incubated with Tb.14, fixed and prepared for visualisation using 
a time-resolved confocal fluorescence microscope. To obtain 
terbium-based signals, emission was recorded as a lifetime map 
using pulsed 375 nm laser excitation.  
At concentrations of 10-4 M to 10-6 M, no metal-based signals 
were observed. Upon increasing probe concentrations to 
10-3 M, ring-like structures of pseudo-intensity on the cellular 
periphery were evident within the stimulated group, (Figure 
7A), as were randomly speckled areas of increased signal. 
Within the stimulated group, presence of terbium-based signals 
were found, whereas no long-lived emission components were 
obtained in unstimulated samples (figure 7B). The overall 
averaged cellular decay times within the stimulated group of 
~20 μs are short compared to lanthanide-only emission 
observed in a cuvette. However, it should be noted that these 
preliminary data were obtained using TCSPC methods including 
the entire range of emission lifetimes, rather than using time-
gated methods to measure phosphorescence alone. Hence, the 
calculated average lifetimes in Fig. 7 include all cellular emission 
including autofluorescent background signals (typically sub 10 
ns) and short-lived Quin C1-based emission. Although 
lanthanide complexes are typically less prone to quenching by 
cellular material than organic dyes due to the triplet nature of 
the emission, it is also possible that the cellular lifetime of the 
complex differs from the solution lifetime. However, while the 
average lifetime method does not demonstrate any ms 
component to the decay, the observed 20 µs average is a 
demonstration of uptake of the complex in stimulated cells 
being in the order of 103 x the average lifetime observed in 
unstimulated cells. The pattern of attachment observed in 
stimulated samples is consistent with images previously 
observed using fluorescently tagged peptides.65  In the study, 
attachment to the FPRs in unstimulated neutrophils  occurred 
uniformly distributed throughout the cell. In contrast, for 
stimulated neutrophils peptide-labelled receptors accumulated 
around the cell periphery or, in a further cell subset, in areas of 
receptor clusters.  
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Conclusions 
Lanthanide frameworks tethered to a small-molecule FPR2/ALX 
ligand were described in this work and their ability to act as 
cellular imaging probes was investigated. The targeting moiety, 
Quin C1, was found to act as an efficient sensitising unit for 
terbium-emission, whereas the europium analogue appeared 
largely non-luminescent under time-gated conditions. Proton 
NMR spectroscopy of Eu.14 revealed typical DOTA-type signals. 
Attachment of the targeting group was found to result in a 
relative increase of the TSAP isomer (and thus preferable water 
exchange properties), which was also reflected in the 
comparatively high r1 value of 6.9 mM-1s-1 at 400 MHz and 294 
K (compared to typical r1 values of ~3-5 mM-1s-1 for 
commercially used contrast agents based on octadentate 
metal-binding frameworks). In vitro testing of compound Tb.14 
was conducted to examine the effects on neutrophil functional 
responses in physiological and pathological conditions. We 
ascertained that neutrophil functions remained intact at certain 
concentrations of Tb.14. Despite weak cellular signals, a time-
resolved microscopy proof of concept experiment confirmed 
preferential uptake of Tb.14 occurred in activated cells, and 
distinctive cellular morphologies were observed, whereas no 
observable long-lived signals were noted in unstimulated 
groups. 
Experimental 
Materials and general procedures 
Reagents were bought from Sigma Aldrich or Fisher Scientific 
and used without further purification. Deuterated solvents 
were bought from Goss Scientific. 1H-NMR and 13C-NMR spectra 
were recorded on a Bruker AMX-500 spectrometer at room 
temperature unless stated otherwise. Coupling constants are 
quoted in Hertz (Hz) and multiplicities are abbreviated as: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet and br 
= broad. Electrospray Time-of- Flight and MALDI mass spectra 
were obtained using a Waters LCT Premier. Thin-layer 
chromatography was conducted using pre-coated Silica gel 60, 
F254 plates with a thickness of 0.2 nm. Column chromatography 
was performed using silica gel or Sephadex-G10 and laboratory 
grade solvents, under mild pressure.  
 
Synthetic procedures 
Compounds 2, 3 ,4 ,5 and 6 were prepared as detailed below, 
using procedures that had been modified from reference.22 
 
Methyl 4-butoxybenzoate (2) 
Potassium carbonate (6.83 g, 50 mmol) and methyl 4-
hydroxybenzoate (5.00 g, 33 mmol) were dissolved in methanol 
(60 mL) and stirred under nitrogen at 0°C for 20 minutes. 1-
Bromobutane (4.97 g, 37 mmol) was added dropwise before the 
mixture was heated at reflux for 23 hours. The solvents were 
removed in vacuo, the reaction mixture was dissolved in 
dichloromethane (50 mL), washed with water (3 x 50 mL), brine 
(2 x 50 ml), dried over magnesium sulphate and concentrated. 
Purification was achieved by silica column chromatography in 
dichloromethane/petroleum ether (3:1) and yielded a clear oil 
(4.09 g, 60 %). 1H-NMR (400 MHz, CDCl3) δH (ppm): 0.99 (3H, t, 
3JHH = 7.4 Hz), 1.51 (2H, m, 3JHH = 7.6 Hz), 1.80 (2H, m, 3JHH = 6.5 
Hz), 3.89 (3H, s), 4.02 (2H, t, 3JHH = 6.5 Hz), 6.91 (2H, d, 3JHH = 8.9 
Hz), 7.98 (2H, d, 3JHH = 8.9 Hz).  
CI+: m/z 209 {M+H}+, 226 {M+NH4}+.  
 
4-Butoxybenzohydrazide (3) 
Compound 2 (2.70 g, 13 mmol) and hydrazine monohydrate 
(2.60 g, 52 mmol) were dissolved in ethanol (50 mL) and heated 
at 65°C under a nitrogen atmosphere for 24 hours, before 
further 4 equivalents of hydrazine monohydrate were added. 
The reaction was heated for further 30 hours. Subsequently, the 
reaction mixture was concentrated in vacuo and the resulting 
oil was purified by activated alumina column chromatography 
(Brockman grade V), eluting initially with dichloromethane. 
Once the starting material had eluted, a methanol gradient (up 
to 20 %) was added to afford a crystalline white solid (1.90 g, 70 
%). 1H-NMR (400 MHz, CDCl3) δH (ppm): 0.99 (3H, t, 3JHH = 7.4 
Hz), 1.51 (2H, m, 3JHH = 7.6 Hz), 1.79 (2H, m, 3JHH = 6.5 Hz), 4.01 
(2H, t, 3JHH = 6.5 Hz), 4.07 (2H, br, -NH2), 6.93 (2H, d, 3JHH= 8.9 
Hz, Ha), 7.70 (2H, d, 3JHH = 8.9 Hz, Hb). ES+: m/z 209 {M+H}+ 
 
2-(4-Butoxybenzoyl)hydrazide 2-nitro-benzoic acid (4) 
4-Butoxybenzohydrazine (1.80 g, 9 mmol) and potassium 
carbonate (1.20 g, 9 mmol) were dissolved in dichloromethane 
at 0°C under a nitrogen atmosphere. 2-Nitro-benzoyl chloride 
(1.0 mL, 7.8 mmol) was added slowly to the solution, which was 
gradually allowed to warm to room temperature. After stirring 
for further 15 hours, the reaction mixture was washed with 
water (2 x 50 mL) and brine (2 x 50 mL), the organic fractions 
were combined and dried over magnesium sulphate before the 
remaining solvents were removed in vacuo to yield a pale yellow 
solid (1.38 g, 43 %). 1H-NMR (400 MHz, MeOD) δH (ppm): 1.01 
(3H, t, 3JHH = 7.4 Hz), 1.53 (2H, m, 3JHH = 7.4 Hz), 1.80 (2H, m, 3JHH 
= 6.4 Hz), 4.07 (2H, t, 3JHH = 6.4 Hz), 7.01 (2H, d, 3JHH = 8.9), 7.72-
8.16 (6H, br).   
ES+: m/z 358 {M+H}+ 
 
2-(4-Butoxybenzoyl)hydrazide 2-amino-benzoic acid (5)  
Compound 4 (1.38 g, 3.8 mmol) was dissolved in a mixture of 
acetic acid and dichloromethane (1:1, 80 mL) at 0°C. Excess zinc 
dust (2.50 g, 38.4 mmol) was added to the stirring mixture 
which was subsequently gradually allowed to warm to room 
temperature. After 16 hours, the mixture was filtered through 
celite and washed with dichloromethane (10 x 20 mL). The 
solvents were removed in vacuo, before the reactants were 
dissolved in dichloromethane, washed with saturated sodium 
bicarbonate (3 x 50 mL) and dried over magnesium sulphate to 
yield an off-white solid (0.87 g, 70 %). 1H-NMR (400 MHz, 
MeOD) δH (ppm): 1.01 (3H, t, 3JHH = 7.4 Hz), 1.54 (2H, m, 3JHH = 
7.6 Hz), 1.79 (2H, m, 3JHH = 6.4 Hz), 4.07 (2H, t, 3JHH = 6.4 Hz), 6.75 
(2H, m), 7.02 (2H, m), 7.32 (1H, m), 7.73 (1H, m), 7.90 (2H, m). 
ES+: m/z 368 {M+MeCN} + 
 
Quin C1 (6) 
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2-(4-Butoxybenzoyl)hydrazide 2-amino-benzoic acid (0.54 g, 1.6 
mmol) and 4-methoxy benzaldehyde (0.27 g, 2.0 mmol) were 
dissolved in ethanol (20 ml) and heated at reflux for an hour 
before addition of citric acid (0.38 g, 2.0 mmol). The reagents 
were further refluxed for 48 hours. Residual solvent was 
removed in vacuo and the reaction mixture was dissolved in 
dichloromethane and filtered. The filtrate was purified by silica 
column chromatography eluting with a dichloromethane and 
acetone gradient of 0 % - 50 % to yield a white solid (0.59 g, 83 
%). 1H-NMR (400 MHz, d6-acetone) δH (ppm): 0.95 (3H, t, 3JHH = 
7.4 Hz), 1.47 (2H, m, 3JHH = 7.6 Hz), 1.74 (2H, m, 3JHH = 6.5 Hz), 
3.78 (3H, s),  4.02 (2H, t, 3JHH = 6.5 Hz), 6.30 (2H, br), 6.83 (1H, 
td, 3Jortho = 7.1 Hz, 4Jmeta = 1.0 Hz), 6.90 (5H, m), 7.35 (1H, td, 3Jortho 
= 8.0 Hz, 4Jmeta = 1.6 Hz), 7.49 (2H, d, 3Jortho = 8.6), 7.66 (2H, m), 
7.84 (1H, dd, 3Jortho = 7.8 Hz, 4Jmeta = 1.5 Hz), 9.38 (1H, br). 13C-
NMR (400 MHz, d6-acetone) δH (ppm): 14.1, 19.8, 31.9, 55.6, 
68.5, 74.8, 114.4, 114.8, 115.5, 119.1, 129.3, 130.2, 130.4, 
134.6, 149.7, 161.4, 162.9, 165.3, 166.3, 180.7.  
HRMS: m/z calculated: 446.2080, found: 446.2089 for {M+H}+ 
 
Quin C1-acetyl chloride (7) 
Compound 6 (0.10 g, 0.22 mmol) and triethylamine (0.03 g, 0.33 
mmol) were dissolved in dichloromethane (3 mL) under a 
nitrogen atmosphere. The stirring solution was immersed in an 
ice/acetone bath and chloroacetyl chloride (0.030 g, 0.26 mmol) 
in dichloromethane (2 mL) was added dropwise. The reaction 
mixture was gradually warmed to room temperature and 
stirred overnight, before it was washed with water (2 x 5 mL) 
and dried over magnesium sulphate. Purification was achieved 
by silica column chromatography eluting with a 
dichloromethane/acetone mixture (95:5) to afford an off-white 
solid (0.07 g, 60 %). 1H-NMR (400 MHz, d6-acetone) δH (ppm): 
0.97 (3H, t, 3JHH = 7.4 Hz), 1.50 (2H, m, 3JHH = 7.6 Hz), 1.78 (2H, 
m, 3JHH = 7.2 Hz), 3.72 (3H, s), 4.08 (2H, t, 3JHH = 6.5 Hz), 4.84 (2H, 
br), 6.81 (2H, dt, 3Jortho = 8.9 Hz, 4Jmeta = 2.1 Hz), 7.02 (2H, m), 7.13 
(1H, br, s), 7.39 (3H, m), 7.58 (2H, m), 7.96 (3H, m), 10.37 (1H, 
br). 13C-NMR (400 MHz, d6-acetone) δH (ppm): 13.1, 18.8, 30.9, 
54.5, 67.6, 113.7, 114.1, 124.0, 126.4, 127.7, 128.5, 129.6, 
132.9, 159.8, 160.4, 162.5, 165.7.  






tetraazacyclododecane (11)42 and 1,4,7-Tris(carbonylmethyl)-
10-(aminoethyl-N-acetyl)-1,4,7,10- tetraazacyclododecane 
(12)42 were prepared as detailed in the respective references.  
 
Preparation of Ln.1342  
Compound 12 and the respective lanthanide salt were dissolved 
in water in a 1:1.1 molar ratio, the pH was adjusted to 5.5 and 
the solution was stirred overnight at room temperature. 
Subsequently, the pH of the mixture was adjusted to 10 using a 
sodium hydroxide solution (1 M) and stirred for 45 minutes. The 
suspension was centrifuged and filtered to remove inorganic 
solids. Next, the pH of the filtrate was readjusted to 7 using a 
hydrochloric acid solution (1 M) and a xylenol orange test was 
performed. Water was removed in vacuo and the residue was 
recrystallised from a methanol and diethyl ether mixture and 
repeatedly washed with diethyl ether. Tb.13: (0.05 g, 59 %). IR 
(solid) in cm-1: 3472, 2359, 1599, 1438, 1406, 1256, 1168, 1036. 
HRMS: m/z calculated: 603.1575 found: 603.1580 for {M+H}+. 
Eu.13: (0.21 g, 88 %). 1H-NMR (400 MHz, D2O) δH (ppm): -16.66, 
-16.20, -15.60, -14.97, 14.67, -14.19, -13.91, -12.60, -11.58, -
10.91, -9.41, -8.47 to -6.95, -6.68, -5.53, -5.02, -4.25, -3.24, -
2.31, -1.72, -1.03, -0.45, 0.38, 1.17, 1.48, 2.49, 2.81 – 4.51, 6.78, 
10.53, 11.30, 11.77 – 12.85, 13.52, 30.74, 31.88, 33.70, 34.07. 
HRMS: m/z calculated: 595.1531 found: 595.1548 for {M+H}+. 
Gd.13: (0.05 g, 35 %). HRMS: m/z calculated: 602.1574, found: 
602.1576 for {M+H}+  
 
Preparation of Ln.14 
Potassium carbonate and Ln.13 (in 5:1 molar ratios) were 
suspended in acetonitrile and stirred for half an hour before 
addition of 7 (1 equivalent). The mixture was heated at 60°C for 
two days. Inorganic salts were removed by filtration and 
residual solvents were evaporated to yield a white solid. The 
crude product was isolated by Sephadex G-10 size exclusion 
chromatography eluting with MilliQ water. Tb.14: (0.02 g, 25 
%). IR (solid) in cm-1: 2361, 1607, 1251, 1173. HRMS: m/z 
calculated: 1089.4792, found: 1089.4794 for {M+H}+. Eu.14: 1H-
NMR (400 MHz, D2O) δH (ppm): -17.17 to -15.97, -15.76, -13.40, 
-12.79 to -10.07, -9.37, -8.25 to-6.79, -6.59, -5.38, -4.85, -3.28, -
2.59 to -1.77, -1.00, -0.45, 0.51, 0.96, 1.26, 1.48, 1.79, 1.91, 2.09, 
2.69, 3.52-4.27, 5.89, 5.94, 5.99, 6.72-8.55, 10.92-14.33, 29.55-
34.30. HRMS: m/z found: 1182.5885 for {M+H2O+2 MeCN+H}+. 
Gd.14: (0.02 g, 30 %). HRMS m/z: calculated: 1087.3524, found: 
1087.3661 for {M+H} +  
 
X-ray crystal structure of 6 
Crystal data for 6: C26H27N3O4, M = 445.50, monoclinic, P21/c 
(no. 14), a = 14.1692(8), b = 13.5603(6), c = 12.7578(7) Å, β = 
110.407(7)°, V = 2297.4(2) Å3, Z = 4, Dc = 1.288 g cm–3, μ(Mo-Kα) 
= 0.088 mm–1, T = 173 K, colourless tabular needles, Agilent 
Xcalibur 3 E diffractometer; 4582 independent measured 
reflections (Rint = 0.0174), F2 refinement,66,67 R1(obs) = 0.0527, 
wR2(all) = 0.1405, 3195 independent observed absorption-
corrected reflections [|Fo| > 4σ(|Fo|), completeness to 
θfull(25.2°) = 98.8%], 316 parameters. CCDC 1945848. 
The C3-bound p-methoxyphenyl group, as well as C3 itself, in 
the structure of 6 was found to be disordered. Two orientations 
were identified of ca. 73 and 27% occupancy, their geometries 
were optimised, the thermal parameters of adjacent atoms 
were restrained to be similar, and only the non-hydrogen atoms 
of the major occupancy orientation were refined anisotropically 
(those of the minor occupancy orientation were refined 
isotropically). As a consequence of this disorder the N4–H 
hydrogen atom was also disordered across two sites, and so 
rather than being found from a ΔF map the two orientations 
were added in idealised positions with riding thermal 
parameters. The N11–H hydrogen atom, by contrast, was 
located from a ΔF map and refined freely subject to an N–H 
distance constraint of 0.90 Å. 
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Photophysical measurements 
UV-vis absorption spectra were recorded on a Perkin Elmer 650 
spectrometer in quartz cuvettes. Concentrations were adapted 
to ensure a sensible absorbance range. Fluorescence excitation 
and emission spectra were obtained using a Varian Cary Eclipse 
spectrophotometer.  
Lanthanide-based lifetimes were measured using a Varian Cary 
Eclipse spectrophotometer in the phosphorescence mode, 
using 1 mM solutions in water or deuterium oxide. The 
integrated intensity was recorded after excitation of the 
samples at 350 nm. The gate time was fixed at 0.1 ms with both 
excitation and emission slits set at 20 nm. The resulting decay 
curves were fitted to a single exponential decay in Microsoft 
Excel. Hydration number (q-values) were calculated according 
to the following equation.45 
 
𝑞𝑞 = 𝐴𝐴(𝜏𝜏𝐻𝐻2𝑂𝑂−1 − 𝜏𝜏𝐷𝐷2𝑂𝑂−1 − 𝐵𝐵) 
 
with A = 5 ms and B = 0.06 ms-1 for terbium.68 
Short-lived organic component luminescence lifetimes were 
assessed in methanol solutions on a time resolved PicoQuant 
FluoTime 300 with a 375 nm picosecond pulsed laser using 




Gd(III) complexes were dissolved in water at 3 different molar 
concentrations. The three solutions and a water standard were 
added into a glass capillary of 1.7 mm diameter, sealed and 
inserted into an NMR tube containing D2O. Concentrations of 
Gd(III) present were assessed by measuring the difference in 
solvent shifts according to the magnetic susceptibility 
measurements conducted using the Evans method.69 T1 
measurements were carried out using a Bruker Advance 400 
spectrometer and inversion recovery measurements. Relaxivity 
values were calculated from the samples using a graphical 
procedure as described in the literature.62 The longitudinal 
relaxation time (T1) of Gd.14 in water was determined at three 
distinct molar concentrations on a 400 MHz NMR spectrometer 
at 294 K. In addition, T1 for just water (T1,0) was determined 
under equivalent conditions.  
 
Cellular studies 




Blood samples were collected by healthcare professionals from 
healthy volunteers after obtaining informed consent (50 mL). 
The study was approved by the institutional review board of the 
LSUHSC-S (STUDY00000261) and conducted in accordance with 
the Declaration of Helsinki. After discarding approximately the 
first 3 mL (to avoid thrombin contamination), 45 mL of the 
sample were mixed with anticoagulant citrate dextrose (ACD) 
solution (5 mL). The samples were centrifuged (800 rpm for 20 
minutes at room temperature) and the upper layer of plasma 
was removed before adding 1 x PBS (10 mL). Subsequently, 6% 
dextran (v/w, 1.8g in 30 mL 1x PBS) solution (8 mL) was added, 
the sample was gently inverted several times and left to 
sediment for 15 minutes. The leukocyte layer was collected and 
separated over a Histopaque 1077 gradient (10 mL per tube). 
After centrifugation (1500 rpm for 30 minutes at room 
temperature), the supernatant was removed. Cold water (9 mL) 
was added in order to lyse residual red blood cell, and 
subsequently mixed with 10 x PBS (1 mL). The volume was made 
up to 40 mL using 1 x PBS and centrifuged (1000 rpm for 10 
minutes at room temperature). The supernatant was removed, 
and the cells were resuspended in 1 x PBS (5 mL) and the 
procedure was repeated. Finally, neutrophils were resuspended 
DMEM with 3% FCS (10 mL). The cells were counted using a 
Neubauer hemocytometer (diluted 1:1 with trypan blue) and 
the resulting cell count was diluted respectively for the number 
of cells required per assay performed. 
 
Chemotaxis assay 
Chemotaxis assays were run using 3 μm pore size ChemoTx® 
System 96 well plates (Neuro Probe, USA). LTB4 (10-6 M, 29 μL, 
Sigma Aldrich) as a chemotactic stimulus or PBS as a control (29 
μL) were added to the bottom of the wells. Freshly isolated 
neutrophils at a concentration of 4 x 106 cells/mL in DMEM and 
3% fetal calf serum (FCS) were treated with vehicle (PBS) or 
varying concentrations of the compound for 10 minutes prior to 
addition to the top of the well plate membranes (25 μL). The 
plates were incubated for 3 hours at 37°C with 5% CO2 before 
removal of the membrane. Migrated cells were manually 
counted using a Neubauer hemocytometer after dilution in a 
1:1 ratio with trypan blue.  
 
Transmigration assay 
To assess cellular transmigration, 24-well plate inserts were 
treated with fibronectin for 30 minutes, before a monolayer of 
human umbilical vein endothelial cells (HUVECs, 32,000 cell/200 
μL) were grown for 72 hours. HUVEC media was removed and 
neutrophils (106 cells/mL in DMEM and 3% FCS) that had been 
pre-treated with vehicle or varying compound concentrations 
for 10 minutes, were added to the inserts (500 μL). PBS (vehicle, 
500 μL) or LTB4 (10-6 M, 500 μL) were added into a fresh 24-well 
plate set up and the inserts were transferred before incubation 
(3 hours at 37°C with 5% CO2). Migrated cells were manually 
counted as described above.  
 
Myeloperoxidase assay 
Myeloperoxidase (MPO) release was quantified from cells that 
had been pre-activated by the transmigration assay. In order to 
achieve this, the neutrophil supernatant (20 μL) was collected 
from the bottom of transmigration plates and mixed in a 4:1 
ratio with a 9:1:0.1 mixture of solutions A, B and C respectively 
that had been previously prepared. Solution A was made up of 
5.4 g KH2PO4, 1.875 g EDTA and 5 mL Triton X-100. Solution B 
was a solution of 3,3’,5,5’- tetramethylbenzidine (TMB, 10 mM) 
in acetone (2 mL) and solution C was an aqueous solution of 
hydrogen peroxide (30%, 25 µL) in water (10 mL). The cellular 
mixture was incubated at room temperature for approximately 
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5 minutes until a colour change occurred and the reaction was 
terminated by addition H2SO4 (1 M, 25 µL). Absorbance was 
read at 450 nm relative to a standard.  
 
Time-resolved microscopy 
Neutrophils were pre-treated with TNFα (50 ng/mL, 30 minutes) 
or with PBS (control) and incubated with varying concentrations 
of compound or vehicle for 45 minutes (37 0C, 5 % CO2). Cells 
were seeded on poly-L-lysine sheets (300,000 cells per sheet) 
and fixed using paraformaldehyde (20 minutes) followed by 
direct transfer onto Fluoromont G coated glass slides. The 
sheets were firmly adhered to the slides using a nail base coat. 
Visualisation was performed on a MicroTime 200 (PicoQuant) 
time resolved confocal fluorescence microscopy system 
consisting of an Olympus IX73 confocal microscope fitted with 
a x100 oil objective excited with a picosecond pulsed 375 nm 
laser and coupled to a TimeHarp SPAD TCSPC unit. The single 
pixel decay profiles were analysed using the SymphoTime 64 
software package. 
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